Objective: To evaluate the clinical efficacy and safety of lacosamide (LCM) in the treatment of children with epilepsy. Methods: Fifty-eight children diagnosed with epilepsy and treated with LCM were retrospectively analyzed. The epilepsy frequencies of 3 months

6 months and 12 months after the start of LCM treatment were recorded and compared with the baseline monthly frequency. The clinical efficacy and adverse drug reactions were evaluated. Results: The dosage of LCM during the maintenance period was from 2.82 to 20.00 (7.03±2.90) mg/(kg·d). Forty children (69.0%) at the last visit responded to LCM treatment

demonstrating more than or equal to 50% reduction in epilepsy frequencies. The rate of complete control of epilepsy increased over time

respectively 15.5%

20.7% and 24.1% at 3

6 and 12 months. The proportion of abnormal electroencephalogram in the ineffective group was significantly higher than that in the effective group (P<0.05). The less the number of combined use of anti-seizure medications and the earlier the addition of LCM

the higher the possibility of complete remission of epilepsy (P<0.05). Twenty (34.5%) children had at least one adverse drug reaction

and the common adverse drug reactions were dizziness

somnolence

fatigue and nausea and vomiting. Conclusion: LCM is clinically effective in the treatment of children with epilepsy

with mild adverse drug reactions and good tolerance.